{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T22:54:45Z","timestamp":1792364085649,"version":"4.4.0"},"reference-count":28,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T00:00:00Z","timestamp":1648598400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>We retrospectively analyzed the clinical and laboratory data of patients diagnosed with anti-transcriptional intermediary factor 1 (TIF-1\u03b3) antibody-positive polymyositis (PM)\/dermatomyositis (DM) to clarify the characteristics of this disease. We identified 14 patients with TIF-1\u03b3 antibody-positive DM (TIF-1\u03b3 DM), 47 with anti-aminoacyl-tRNA synthetase antibody (ARS)-positive PM\/DM, and 24 with anti-melanoma differentiation-associated gene 5 antibody (MDA-5)-positive PM\/DM treated at the Kurume University Hospital between 2002 and 2020. Patients with TIF-1\u03b3 DM were significantly older than the other two groups. Nine patients with TIF-1\u03b3 DM were female, thirteen patients had DM, and one had clinically amyopathic DM. Primary malignant lesions were lung (3), uterus (2), colon (2), breast (2), ovary (1), lymphoma (1), and unknown (2). Cutaneous manifestation and dysphagia were the most common symptoms in TIF-1\u03b3 DM. Erythema (9\/14), the V-neck sign (8\/14), heliotrope (9\/14), and nailfold telangiectasia (14\/14) were significantly more common in TIF-1\u03b3 DM. Furthermore, no patients with TIF-1\u03b3 DM had interstitial lung abnormality on high-resolution CT. In patients with TIF-1\u03b3 DM, the frequency of dysphagia and unusual erythema, particularly that which spreads from the trunk, and nailfold telangiectasia, were characteristic findings. In most patients with TIF-1\u03b3 DM, it is necessary to administer other immunosuppressive drugs along with glucocorticoids.<\/jats:p>","DOI":"10.3390\/jcm11071925","type":"journal-article","created":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T21:28:39Z","timestamp":1648675719000},"page":"1925","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Clinical Characteristics of Anti-TIF-1\u03b3 Antibody-Positive Dermatomyositis Associated with Malignancy"],"prefix":"10.3390","volume":"11","author":[{"given":"Yumi","family":"Harada","sequence":"first","affiliation":[{"name":"Division of Respirology, Department of Medicine, Neurology and Rheumatology, Kurume University School of Medicine, Kurume 830-0011, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6972-1338","authenticated-orcid":false,"given":"Masaki","family":"Tominaga","sequence":"additional","affiliation":[{"name":"Division of Respirology, Department of Medicine, Neurology and Rheumatology, Kurume University School of Medicine, Kurume 830-0011, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eriko","family":"Iitoh","sequence":"additional","affiliation":[{"name":"Division of Respirology, Department of Medicine, Neurology and Rheumatology, Kurume University School of Medicine, Kurume 830-0011, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinjiro","family":"Kaieda","sequence":"additional","affiliation":[{"name":"Division of Respirology, Department of Medicine, Neurology and Rheumatology, Kurume University School of Medicine, Kurume 830-0011, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuma","family":"Koga","sequence":"additional","affiliation":[{"name":"Division of Respirology, Department of Medicine, Neurology and Rheumatology, Kurume University School of Medicine, Kurume 830-0011, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiminori","family":"Fujimoto","sequence":"additional","affiliation":[{"name":"Department of Radiology, Center for Diagnostic Imaging, Kurume University School of Medicine, Kurume 830-0011, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomonori","family":"Chikasue","sequence":"additional","affiliation":[{"name":"Department of Radiology, Center for Diagnostic Imaging, Kurume University School of Medicine, Kurume 830-0011, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Obara","sequence":"additional","affiliation":[{"name":"Biostatistics Center, Kurume University, Kurume 830-0011, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuyuki","family":"Kakuma","sequence":"additional","affiliation":[{"name":"Biostatistics Center, Kurume University, Kurume 830-0011, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0295-0301","authenticated-orcid":false,"given":"Hiroaki","family":"Ida","sequence":"additional","affiliation":[{"name":"Division of Respirology, Department of Medicine, Neurology and Rheumatology, Kurume University School of Medicine, Kurume 830-0011, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomotaka","family":"Kawayama","sequence":"additional","affiliation":[{"name":"Division of Respirology, Department of Medicine, Neurology and Rheumatology, Kurume University School of Medicine, Kurume 830-0011, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoaki","family":"Hoshino","sequence":"additional","affiliation":[{"name":"Division of Respirology, Department of Medicine, Neurology and Rheumatology, Kurume University School of Medicine, Kurume 830-0011, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,3,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"433","DOI":"10.21037\/atm-20-5175","article-title":"Dermatomyositis Autoantibodies: How Can We Maximize Utility?","volume":"9","author":"Hodgkinson","year":"2021","journal-title":"Ann. Transl. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3682","DOI":"10.1002\/art.22164","article-title":"A Novel to a 155-Kd Protein Is Associated with Dermatomyositis","volume":"54","author":"Targoff","year":"2006","journal-title":"Arthritis Rheum."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1097\/BOR.0000000000000329","article-title":"Recent Advances in Dermatomyositis-Specific Autoantibodies","volume":"28","author":"Fujimoto","year":"2016","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"100148","DOI":"10.1016\/j.jtauto.2022.100148","article-title":"Positioning of myositis-specific and associated autoantibody (MSA\/MAA) testing in disease criteria and routine diagnostic work-up","volume":"5","author":"Bonroy","year":"2022","journal-title":"J. Transl. Autoimmun."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.rmed.2016.10.019","article-title":"Comprehensive Assessment of Myositis-Specific Autoantibodies in Polymyositis\/Dermatomyositis-Associated Interstitial Lung. Disease","volume":"121","author":"Hozumi","year":"2016","journal-title":"Respir. Med."},{"key":"ref_6","first-page":"409","article-title":"Dermatomyositis and Malignancy","volume":"65","author":"Hu","year":"2019","journal-title":"Can. Fam. Physician"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and Dermatomyositis (First of Two Parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/rheumatology\/kel161","article-title":"Identification of a Novel Autoantibody Reactive with 155 and 140-kDa Nuclear Proteins in Patients with Dermatomyositis: An Association with Malignancy","volume":"46","author":"Kaji","year":"2007","journal-title":"Rheumatology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/nrc3139","article-title":"TRIM Proteins and Cancer","volume":"11","author":"Hatakeyama","year":"2011","journal-title":"Nat. Rev. Cancer."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"979","DOI":"10.3389\/fonc.2019.00979","article-title":"The Roles of TIF1\u03b3 in Cancer","volume":"9","author":"Yu","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/25785826.2020.1791402","article-title":"Transcriptional Intermediary factor 1 (TIF1) and Anti-TIF1\u03b3 Antibody-Positive Dermatomyositis","volume":"44","author":"Kotobuki","year":"2021","journal-title":"Immunol. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1038\/sj.onc.1202655","article-title":"TIF1gamma, a Novel Member of the Transcriptional Intermediary factor 1 Family","volume":"18","author":"Venturini","year":"1999","journal-title":"Oncogene"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S0140-6736(00)03540-6","article-title":"Frequency of Specific Cancer Types in Dermatomyositis and Polymyositis: A Population-Based Study","volume":"357","author":"Hill","year":"2001","journal-title":"Lancet"},{"key":"ref_14","first-page":"5960","article-title":"Characteristics and Predictors of Malignancy in Dermatomyositis: Analysis of 239 Patients from Northern China","volume":"16","author":"Liu","year":"2018","journal-title":"Oncol. Lett."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/j.1365-2133.2009.09274.x","article-title":"Malignancies Associated with Dermatomyositis and Polymyositis in Taiwan: A Nationwide Population-Based Study","volume":"161","author":"Huang","year":"2009","journal-title":"Br. J. Dermatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.3899\/jrheum.090549","article-title":"Malignancy Is Associated with Dermatomyositis but Not Polymyositis in Northern New England, USA","volume":"36","author":"Antiochos","year":"2009","journal-title":"J. Rheumatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1097\/BOR.0b013e3283317fa5","article-title":"Paraneoplastic Myopathy","volume":"21","author":"Ponyi","year":"2009","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_18","first-page":"1601","article-title":"Characteristics of Dermatomyositis Patients with and without Associated Malignancy","volume":"19","author":"Lauinger","year":"2021","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s12016-015-8496-5","article-title":"Cutaneous Manifestations in Dermatomyositis: Key Clinical and Serological Features\u2014A Comprehensive Review","volume":"51","author":"Muro","year":"2016","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1111\/bjd.15020","article-title":"Cutaneous Features of Dermatomyositis Associated with Myositis-Specific Antibodies","volume":"176","author":"Daly","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.3899\/jrheum.200399","article-title":"Ulcerative Paraneoplastic Dermatomyositis in the Setting of Positive Transcriptional Intermediary factor 1-\u03b3 Antibody","volume":"48","author":"Sluzevich","year":"2021","journal-title":"J. Rheumatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.jaad.2014.12.009","article-title":"Distinctive Cutaneous and Systemic Features Associated with Antitranscriptional Intermediary factor-1\u03b3 Antibodies in Adults with Dermatomyositis","volume":"72","author":"Fiorentino","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1212\/WNL.0000000000002863","article-title":"Anti-TIF1-\u03b3 Antibody and Cancer-Associated Myositis: A Clinicohistopathologic Study","volume":"87","author":"Hida","year":"2016","journal-title":"Neurology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"14","DOI":"10.5114\/reum.2016.58756","article-title":"Clinical Characteristics of Patients with Anti-TIF1-\u03b3 Antibodies","volume":"54","author":"Masiak","year":"2016","journal-title":"Reumatologia"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1093\/rheumatology\/39.6.632","article-title":"Serum KL-6 in adult patients with polymyositis and dermatomyositis","volume":"39","author":"Kubo","year":"2000","journal-title":"Rheumatology"},{"key":"ref_26","first-page":"e7049","article-title":"The Value of Intravenous Immunoglobulin Therapy in Idiopathic Inflammatory Myositis in the Current Transformed Era of Biologics","volume":"12","author":"Patwardhan","year":"2020","journal-title":"Cureus"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jaad.2008.02.043","article-title":"The Treatment and Prognosis of Dermatomyositis: An Updated Review","volume":"59","author":"Iorizzo","year":"2008","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/S0190-9622(98)70263-4","article-title":"Dermatomyositis","volume":"39","author":"Kovacs","year":"1998","journal-title":"J. Am. Acad. Dermatol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/7\/1925\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:46:32Z","timestamp":1760136392000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/7\/1925"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,30]]},"references-count":28,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,4]]}},"alternative-id":["jcm11071925"],"URL":"https:\/\/doi.org\/10.3390\/jcm11071925","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,30]]}}}